Alejandra Martínez-Trillos

TL;DR: This work provides the first comprehensive catalog of somatic mutations in CLL with relevant clinical correlates and defines a large set of new genes that may drive the development of this common form of leukemia.

TL;DR: An epigenomic scenario in which differential methylation in the gene body may have functional and clinical implications in leukemogenesis is proposed and recognized a DNA methylation signature that distinguishes new clinico-biological subtypes of CLL.

TL;DR: Observations indicate that driver mutations define distinct disease entities within PMF, which is not only relevant to clinical decision-making, but should also be considered in designing clinical trials.

TL;DR: In this article, the authors constructed tissue microarrays with 157 DLBCL patients homogeneously treated with immunochemotherapy to apply the following immunostaining algorithms: Colomo (MUM1/IRF4, CD10, and BCL6 antigens), Hans (CD10, BCL 6, and MUM 1/ IRF4 plus BCL2), Muris (CD 10 and MCI 1, MCI 2), Choi (GCET1, MUM 3, MCIA 4, CD 10, NCI 3, and NCI 4

TL;DR: Recurrent somatic mutations in POT1 (encoding protection of telomeres 1) are identified in 3.5% of the cases and may facilitate novel approaches for the clinical management of this disease.